173 related articles for article (PubMed ID: 38637883)
21. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
22. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
23. The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors.
Robey RW; Fitzsimmons CM; Guiblet WM; Frye WJE; González Dalmasy JM; Wang L; Russell DA; Huff LM; Perciaccante AJ; Ali-Rahmani F; Lipsey CC; Wade HM; Mitchell AV; Maligireddy SS; Terrero D; Butcher D; Edmondson EF; Jenkins LM; Nikitina T; Zhurkin VB; Tiwari AK; Piscopio AD; Totah RA; Bates SE; Arda HE; Gottesman MM; Batista PJ
Mol Cancer Ther; 2024 Apr; 23(4):464-477. PubMed ID: 38151817
[TBL] [Abstract][Full Text] [Related]
24. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat, a histone deacetylase inhibitor, rescues the angiogenic potential of endothelial colony-forming cells in moyamoya disease.
Jangra A; Choi SA; Koh EJ; Moon YJ; Wang KC; Phi JH; Lee JY; Kim SK
Childs Nerv Syst; 2019 May; 35(5):823-831. PubMed ID: 30815722
[TBL] [Abstract][Full Text] [Related]
26. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Mosleh M; Safaroghli-Azar A; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
[TBL] [Abstract][Full Text] [Related]
27. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat.
Afolabi LO; Bi J; Li X; Adeshakin AO; Adeshakin FO; Wu H; Yan D; Chen L; Wan X
Front Immunol; 2021; 12():701671. PubMed ID: 34531855
[TBL] [Abstract][Full Text] [Related]
28. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
29. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Joseph R; Dasari SK; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Kim MS; Corvigno S; Foster K; Hanjra P; Vu TC; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279277
[TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
Hamam HJ; Palaniyar N
Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
[TBL] [Abstract][Full Text] [Related]
31. Macrophage colony-stimulating factor potentially induces recruitment and maturation of macrophages in recurrent pituitary neuroendocrine tumors.
Matsuzaki H; Komohara Y; Yano H; Fujiwara Y; Kai K; Yamada R; Yoshii D; Uekawa K; Shinojima N; Mikami Y; Mukasa A
Microbiol Immunol; 2023 Feb; 67(2):90-98. PubMed ID: 36461910
[TBL] [Abstract][Full Text] [Related]
32. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
34. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J
Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658
[TBL] [Abstract][Full Text] [Related]
35. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
Mehrpouri M; Momeny M; Bashash D
J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke.
Al Shoyaib A; Alamri FF; Syeara N; Jayaraman S; Karamyan ST; Arumugam TV; Karamyan VT
Neuromolecular Med; 2021 Dec; 23(4):471-484. PubMed ID: 33590407
[TBL] [Abstract][Full Text] [Related]
38. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract][Full Text] [Related]
39. Progress of HDAC inhibitor panobinostat in the treatment of cancer.
Li X; Zhang J; Xie Y; Jiang Y; Yingjie Z; Xu W
Curr Drug Targets; 2014 Jun; 15(6):622-34. PubMed ID: 24597570
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
